REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

Public trial

Evaluation of the cardioprotective effects of Dapagliflozin in patients with Sickle Cell Disease

Date of registration: 10/30/2025 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Assessment of the efficacy of a Dietary Supplement on hair growth or terminal hair density parameters in adults with Androgenetic Alopecia

Date of registration: 06/01/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of Brain Stimulation on balance and walking of patient with Multiple Sclerosis: real case report

Date of registration: 06/01/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Fibromyalgia and its impacts on well-being and functional capacity.

Date of registration: 06/01/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Shoulder Flexibility and Breast Augmentation Surgery: Randomized Study

Date of registration: 04/22/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Heat Shock Protein 27 in Climacteric Women

Date of registration: 06/01/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Effect of mineral and vitamin supplementation in the recovery of burners

Date of registration: 06/01/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Guidance actions for controlling protein in the diet for people with Diabetic Kidney Disease: PROREN project

Date of registration: 06/01/2026 ^(mm/dd/yyyy)
Last approval date : 06/01/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Systematization of Pharmaceutical Services in the Public Health System of the Federal District: Improved Care and Expanded Access

Date of registration: 05/30/2026 ^(mm/dd/yyyy)
Last approval date : 05/30/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Magnetic Stimulation on Hand Grip and Arm Muscles in Post-Stroke Individuals and Healthy Subjects

Date of registration: 05/29/2026 ^(mm/dd/yyyy)
Last approval date : 05/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of quitting smoking on oral health of smokers. Long-term study

Date of registration: 05/29/2026 ^(mm/dd/yyyy)
Last approval date : 05/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Treatment of HPV-related lesions using a new immunotherapy that stimulates the body’s immune defense cells

Date of registration: 05/29/2026 ^(mm/dd/yyyy)
Last approval date : 05/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of two Anesthesia techniques for lower wisdom tooth removal

Date of registration: 05/29/2026 ^(mm/dd/yyyy)
Last approval date : 05/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The use of Elastic Bandages for relieving lower back pain in pregnant women

Date of registration: 05/29/2026 ^(mm/dd/yyyy)
Last approval date : 05/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Electrical Stimulation on penile blood Circulation in young adult men: A Triple-Blind Randomized Controlled Clinical Trial

Date of registration: 05/29/2026 ^(mm/dd/yyyy)
Last approval date : 05/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Picosecond Laser for Treating Flat Scars

Date of registration: 05/28/2026 ^(mm/dd/yyyy)
Last approval date : 05/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of shockwave therapy to improve walking and lower back stability in people with chronic low back pain placebo controlled clinical study

Date of registration: 05/28/2026 ^(mm/dd/yyyy)
Last approval date : 05/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Can brain stimulation improve fluency in sign language: clinical study evaluating brain activity and arm movement

Date of registration: 05/28/2026 ^(mm/dd/yyyy)
Last approval date : 05/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Color changes and wear of clear orthodontic aligners after use in the mouth

Date of registration: 05/27/2026 ^(mm/dd/yyyy)
Last approval date : 05/27/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

How balance and movements relate in people with Autism: a look back study

Date of registration: 05/27/2026 ^(mm/dd/yyyy)
Last approval date : 05/27/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

…
6
7
8
9
10
11
12
13
14
…
472

Username/Password

News

07/10/2026

Trial of fast-tracked new Parkinson’s cell therapy hits ‘critical’ step

07/10/2026 | Andrea Lobo | Parkinson's News Today

https://parkinsonsnewstoday.com/news/trial-fast-tracked-new-parkinsons-cell-therapy-hits-critical-step/

2 groups get commercial 'thaw-and-inject' formulation of sasineprocel

Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial.

This brings the total number of adults with Parkinson’s who received sasineprocel in the ASPIRO trial (NCT06344026) to 15. The Phase 1/2a study, conducted at nine sites across the country, is testing the safety and tolerability of the autologous cell therapy — one that uses a patient’s own cells — for up to five years.

The treatment’s commercial formulation uses what its developer calls cryopreserved “thaw-and-inject” cells that can be administered upon arrival at the clinical site. It was developed to facilitate therapy production and clinical delivery.

“We are proud to reach this important milestone, which reflects meaningful progress in the sasineprocel program and underscores the growing clinical experience with our personalized, autologous approach,” Damien McDevitt, PhD, Aspen’s president and CEO, said in a company press release. “Importantly, the use of our commercial formulation in these [patient groups] represents a critical step toward scalable manufacturing and commercial readiness as we prepare for Phase 3 initiation.”

Sasineprocel is an autologous cell therapy, meaning an individual’s own cells are the basis for the treatment, that aims to replace dopaminergic neurons, the nerve cells lost in Parkinson’s…

07/10/2026

Study of 23,000 patients provides evidence on diabetes management

07/09/2026 | Estado de Minas

https://www.em.com.br/bem-viver/2026/07/amp/7458042-estudo-com-23-mil-pacientes-traz-evidencias-sobre-o-controle-do-diabetes.html

Published in an international journal, Hapvida’s study evaluates the results of the Viver Bem program and highlights improvements in clinical and laboratory indicators

A study published in the international scientific journal BMC Endocrine Disorders on May 27 reveals that patients with type 2 diabetes (T2D) enrolled in the Viver Bem program—a structured diabetes care initiative adopted by Hapvida—showed significant improvements in clinical and laboratory indicators.

Factors such as glycated hemoglobin, blood pressure, weight, and lipid profile were monitored in 23,516 enrolled patients over approximately 20 months, between 2017 and 2023.

In addition to improvements in these indicators, lower operational costs related to emergency room visits, tests, and treatments were recorded compared to eligible patients who were not included in the program.
The study, conducted by the Hapvida Clinical Research Center in partnership with the Federal University of São Paulo and Nove de Julho University, is one of the largest real-world studies on diabetes management ever conducted in Brazil within a supplemental health care system.

“Follow-up of patients included in the program shows that structured chronic care delivers real clinical benefits. Furthermore, a rational strategy for resource allocation can help make health plans more sustainable and accessible. Programs like this demonstrate that providing good care costs less,” says Rodrigo Sardenberg, director of clinical research at Hapvida.

Continuous Monitoring

The Viver Bem Program…

07/10/2026

Study Tests Cell Transplantation as a Treatment for Parkinson's

07/10/2026 | Paloma Oliveto | Correio Brasiliense

https://www.correiobraziliense.com.br/ciencia-e-saude/2026/07/7458373-estudo-testa-transplante-de-celulas-como-tratamento-para-parkinson.html

In a preliminary study involving eight patients, scientists demonstrated the safety of the procedure, which uses embryonic tissue reprogrammed to become neurons. There is still a long way to go before clinical application, but the authors are optimistic

For decades, the treatment of Parkinson’s disease has focused on alleviating the symptoms caused by the progressive loss of neurons that produce dopamine, which is currently achieved through the use of medications. Now, a human study points to a new therapeutic approach: replacing destroyed brain cells with new structures of embryonic origin, genetically programmed to naturally produce the neurotransmitter.

In Parkinson’s disease, the brain loses nerve cells that produce dopamine, leading to symptoms such as slowness of movement, rigidity, gait disturbances, and tremors. Although the most modern medications have revolutionized the treatment of the disease, improving patients’ quality of life, over time these substances often become less effective and can cause neurological, gastrointestinal, and psychiatric side effects, among others.

To address these limitations, researchers from England, Sweden, and the United States tested the safety of transplanting dopamine-producing neurons derived from embryonic stem cells into the brain. As this is still a preliminary study, the research—published in the journal *Nature Medicine* and presented yesterday at the annual meeting of the International Society for Stem Cell Research in Montreal, Canada—was conducted with only eight…

07/09/2026

Paraná Leads in Polylaminin Treatments with the Highest Number of Patients Treated

07/09/2026 | Júlia Moreira/Tribuna do Paraná | Gazeta do Povo

https://www.gazetadopovo.com.br/parana/parana-lidera-aplicacoes-de-polilaminina/

Paraná ranks first in Brazil in the number of polylaminine treatments. As of the end of June, the state had performed 19 procedures using the experimental drug for the treatment of spinal cord injuries, according to data from Laboratório Cristália. This total surpasses the figures for Rio de Janeiro, with 11 applications, and Espírito Santo, with nine. In all, 19 states have already performed at least one application of the substance.

The treatment, which has shown promising results in the recovery of patients with spinal cord injuries, was administered for the first time in Paraná on January 8 of this year at Santa Casa de Maringá. In Curitiba, the first administration took place on March 3, 2026, at Hospital do Trabalhador.

Still in the experimental phase, the drug is used in ongoing clinical trials and also for compassionate use. The Brazilian Health Regulatory Agency (Anvisa) grants authorization for this type of use through an administrative process, but the decision to donate the drug rests with the pharmaceutical company.

Polylaminin administration requires precision in the lesion area
The procedure involves a puncture directly into the affected area. “In layman’s terms, it’s an injection, but technically speaking, it’s a spinal puncture. We go to the patient, study the location of the injury beforehand, and need to be literally surgical. It’s an area of approximately one square centimeter,” explained neurosurgeon João Elias Ferreira El Sarraf, who lives in Paraná and is one of four doctors responsible for administering polylaminin…

07/09/2026

Rethinking Clinical Trial Design and the Immune System in Multiple Sclerosis

07/09/2026 | Ahmed Obeidat/Isabella Ciccone | Neurology Live

https://www.neurologylive.com/view/rethinking-clinical-trial-design-immune-system-ms-ahmed-obeidat

At CMSC 2026, the associate professor of neurology at the Medical College of Wisconsin discussed the need to reconsider clinical trial paradigms by recognizing the role of immune cells

"I want to challenge the concept that the immune system is our enemy in this disease. I want to think of it as maybe as our friend who's just a little bit misbehaving, and we need to put it back in check. We want to redirect the immune system."
Reimagining clinical trial design in multiple sclerosis (MS) has become increasingly important as limitations of traditional efficacy measures, such as relapse rates and MRI lesion activity, have come into sharper focus. Emerging evidence suggests that neurodegeneration and disease progression may continue despite apparent control of inflammatory activity, underscoring the need for end points and therapeutic strategies that prioritize preservation of brain tissue and long-term neurologic function. As understanding of the immunopathology of MS evolves, researchers are reconsidering the role of immune cells not only as drivers of injury, but also as potential mediators of repair and neuroprotection.

At the recently concluded 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 27-29, Charlotte, North Carolina, MS specialist Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, presented a session titled “Changing the Rules: Reimagining Clinical Trials in Multiple Sclerosis.” In this talk, he explored how conventional paradigms that focus predominantly on immune suppression and inflammatory activity may…